Jagsonpal Pharmaceuticals Limited Share Price & Analysis
Price Chart
Fundamentals
Strengths
- Strong return on equity (ROE 16.7%)
- Attractively valued vs sector (P/E 32x vs industry 54.7x)
- Virtually debt-free
Concerns
Peer Comparison
| Company | CMP | Mkt Cap | P/E | P/B | ROE % | ROCE % | D/E |
|---|---|---|---|---|---|---|---|
| SUNPHARMA Sun Pharmaceutical Industries Limited | ₹1,899 | ₹4.6L Cr | 36.1 | 5.46 | 16 | 20.5 | 0.07 |
| DIVISLAB Divi's Laboratories Limited | ₹9,100 | ₹2.4L Cr | 81.1 | 14.42 | 16.5 | 22 | 0.01 |
| TORNTPHARM Torrent Pharmaceuticals Limited | ₹4,857 | ₹1.8L Cr | 82.8 | 19.58 | 27.4 | 15.2 | 0.33 |
| APOLLOHOSP Apollo Hospitals Enterprise Limited | ₹8,650 | ₹1.2L Cr | 59.1 | 13.13 | 21.2 | 17.4 | 0.88 |
| CIPLA Cipla Limited | ₹1,385 | ₹1.1L Cr | 31.3 | 3.25 | 11.6 | 15.5 | 0.01 |
| ZYDUSLIFE Zydus Lifesciences Limited | ₹1,120 | ₹1.1L Cr | 23 | 4.16 | 21.2 | 21.1 | 0.38 |
| LAURUSLABS Laurus Labs Limited | ₹1,840 | ₹99K Cr | 90.9 | 18.74 | 18.3 | 17.8 | 0.46 |
Showing 7 peers in the same sector · Sorted by market cap
Shareholding Pattern
JAGSNPHARM · as of Mar 2026
| Category | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Promoters | 68.48% | 68.09% | 68.04% | 67.98% | 67.82% | 67.77% |
| FII | 0.53% | 0.73% | 1.10% | 2.30% | 2.10% | 2.10% |
| DII | 0.82% | 0.84% | 0.84% | 0.11% | — | — |
| Public | 30.16% | 30.33% | 30.01% | 29.63% | 30.10% | 30.11% |
Latest News
All newsJagsonpal acquires Aequitas Healthcare in strategic expansion move
*Jagsonpal acquires Aequitas Healthcare in strategic expansion move*. Jagsonpal Pharmaceuticals has completed the acquisition of Aequitas Healthcare Private Limited, marking a significant step in its growth strategy. The deal strengthens Jagsonpal’s presence in the specialty pharma segment. Financial terms include acquisition value **over ₹500 crore**, qualifying it as a major corporate event. 📊 *STOCKS:* JAGSNPHARM | 🏢 *SECTOR:* Pharma | #HIGHIMPACT #acquisition
Jagsonpal Pharmaceuticals publishes mandatory newspaper notice
*Jagsonpal Pharmaceuticals publishes mandatory newspaper notice.* This is a routine corporate disclosure as per regulatory requirements. No financial or operational details were provided. Such filings are standard and do not indicate immediate business changes. 📊 *STOCKS:* $JAGSONPAL | 🏢 *SECTOR:* Pharma | #LOWIMPACT #Corporate
Jagsonpal Pharma allots 27,950 shares under ESOP 2022
*Jagsonpal Pharma allots 27,950 shares under ESOP 2022.* The company has issued **27,950 equity shares** pursuant to the exercise of stock options under its Employee Stock Option Plan, 2022. This allotment is part of the company's employee compensation and retention strategy. The shares were issued at a price determined as per SEBI guidelines and the scheme rules. 📊 *STOCKS:* $JAGSONPAL | 🏢 *SECTOR:* Pharma | #LOWIMPACT #ESOP
Jagsonpal Services gets RBI nod for 100% Welcast Finstocks acquisition
*Jagsonpal Services gets RBI nod for 100% Welcast Finstocks acquisition.* The Reserve Bank of India has approved Jagsonpal Services' **100% acquisition** of Welcast Finstocks Private, a move aimed at strengthening its presence in the financial services sector. This strategic acquisition is expected to enhance Jagsonpal’s product offerings and client base. The deal underscores Jagsonpal’s expansion plans in the non-banking finance space. 📊 *STOCKS:* JAGSONPAL | 🏢 *SECTOR:* Corporate | #MEDIUMIMPACT #Acquisition
About Jagsonpal Pharmaceuticals Limited
Incorporated in 1978, Jagsonpal Pharmaceuticals Ltd manufactures and trades pharmaceutical products and active pharmaceutical ingredients[1]
HealthcarePharmaceuticals & Biotechnology